IIM
FATE icon

INTECH Investment Management’s Fate Therapeutics FATE Stock Holding History

INTECH Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,926
Closed -$35.9K – 2157
2026
Q1 		$35.9K Sell
29,926
-21,734
-42% -$26.5K ﹤0.01% 2037
2025
Q4 		$50.8K Sell
51,660
-4,656
-8% -$5.59K ﹤0.01% 2260
2025
Q3 		$71K Sell
56,316
-17,063
-23% -$18.4K ﹤0.01% 2330
2025
Q2 		$82.2K Sell
73,379
-5,004
-6% -$5.82K ﹤0.01% 2340
2025
Q1 		$61.9K Buy
78,383
+38,940
+99% +$47.7K ﹤0.01% 2406
2024
Q4 		$65.1K Buy
39,443
+8,497
+27% +$21.4K ﹤0.01% 2293
2024
Q3 		$108K Buy
+30,946
New +$120K ﹤0.01% 1870

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

INTECH Investment Management's FATE Position: Q2 2026 in Review

INTECH Investment Management sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 29,926 shares — an estimated $35.9K sold.

INTECH Investment Management first reported a position in FATE in Q3 2024 and held it in 7 quarters. The position peaked at $108K in Q3 2024. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • INTECH Investment Management reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • INTECH Investment Management sold 29,926 Fate Therapeutics shares in Q2 2026, an estimated $35.9K.
  • INTECH Investment Management first reported a position in Fate Therapeutics in Q3 2024 and held it in 7 quarters.
  • INTECH Investment Management's Fate Therapeutics position peaked at $108K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.